Meet physician scientist, Dr. Allie Grossmann
Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.
Read Article
-
-
Providence researchers contribute study findings at ASCO 2024 meeting, May 31- June 3
The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.
Read Article
-
Celebrating Women in Science
In honor of International Day of Women and Girls in Science we highlight a researcher at Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute.
Read Article
-
Studies address need for more treatment options in endometrial cancer and AML
New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, and a phase I trial for people with AML assesses a non-engineered natural killer cell therapy
Read Article
-
Promising results of amivantamab studies appear in high-profile journals
New articles co-authored by Dr. Rachel Sanborn feature amivantamab studies for people with NSCLC.
Read Article
-
Immunotherapies for GI and lung cancers evaluated in new studies
A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.
Read Article
-
Genomic testing can improve outcomes for people with advanced cancer, study shows
Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.
Read Article
-
Providence researchers contribute to 21 studies at SITC2023
SITC 2023 provides a glimpse into scientific advances and breakthroughs in cancer immunotherapy by researchers from around the world.
Read Article
-
New studies address unmet needs in treating triple-negative breast cancer
Two new studies available at Earle A. Chiles Research Institute, at division of Providence Cancer Institute of Oregon, to evaluate new treatments for triple-negative breast cancer.
Read Article
-
Dr. Urba receives award for his contributions to science and community
Providence Cancer Institute of Oregon, and research director, Earle A. Chiles Research Institute, Walter J. Urba, M.D., Ph.D., receives award for his contributions to science and community.
Read Article
-
New study aims to fill treatment gap for patients with endometrial cancer
For Gynecologic Cancer Awareness Month, Providence Cancer Institute highlights a clinical trial that evaluates the safety and effectiveness of a new oral treatment for grade 1 endometrial cancer.
Read Article
-
Two trials evaluate new approaches to treating non-Hodgkin and follicular lymphomas
New trial open at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, is enrolling patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Read Article
-
Two new trials enrolling patients with rectal cancer and solid tumors
A phase II trial tests FOLFOX or CAPOX versus FOLFIRINOX in patients with locally advanced rectal cancer, and a phase I trial evaluates TBio-4101 in patients with advanced solid tumors.
Read Article
-
Promising results of Providence-sponsored trial published in npj Breast Cancer
Final outcomes from a Providence Cancer Institute-sponsored phase Ib trial evaluating pembrolizumab with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic TNBC.
Read Article
-
Providence researchers contribute to more than 20 studies presented at ASCO Annual Meeting
Researchers from Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, shared their investigations to advance cancer research and treatments at the premier event.
Read Article
-
Immunotherapies evaluated in new trials for AML, melanoma and solid tumor cancers
New investigator-initiated trial at Providence to evaluate a triple combination of medications for treating melanoma, and two new studies evaluating medication combinations to treat AML.
Read Article
-
Prestigious grant awarded to Providence researcher
Providence researchers awarded an R21 grant from the National Institutes of Health which provides funding for projects with potential to significantly advance biomedical research.
Read Article
-
Three studies highlight the range of our pioneering research
Studies open at Providence Cancer Institute in Oregon for patients with head and neck cancer and patients with breast cancer that has metastasized in the brain.
Read Article
-
Targeted therapies are the focus of new studies for colorectal and bile duct cancers
New trials available at Earle A. Chiles Research Institute for patients with human epidermal growth factor receptor 2 positive (HER2+) colorectal cancer and patients with cholangiocarcinoma.
Read Article
-
Cancer vaccine is focus of breast cancer study at Providence
A new trial offered at Providence Cancer Institute is enrolling patients with early-stage HR-positive and HER2-negative breast cancer.
Read Article
-
Loading More...
